{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,23]],"date-time":"2026-08-23T14:55:39Z","timestamp":1787496939261,"version":"build-2736575974"},"reference-count":37,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2025,1,1]],"date-time":"2025-01-01T00:00:00Z","timestamp":1735689600000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.fr","clinicalkey.jp","clinicalkey.com.au","clinicalkey.es","clinicalkey.com","jns-journal.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of the Neurological Sciences"],"published-print":{"date-parts":[[2025,1]]},"DOI":"10.1016\/j.jns.2024.123356","type":"journal-article","created":{"date-parts":[[2024,12,16]],"date-time":"2024-12-16T02:47:11Z","timestamp":1734317231000},"page":"123356","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":2,"special_numbering":"C","title":["Ofatumumab for multiple sclerosis with disability accumulation"],"prefix":"10.1016","volume":"468","author":[{"given":"Masahiro","family":"Mimori","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsuko","family":"Katsumoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomoko","family":"Okamoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Wakiro","family":"Sato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Youwei","family":"Lin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takashi","family":"Yamamura","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yuji","family":"Takahashi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.jns.2024.123356_bb0005","doi-asserted-by":"crossref","first-page":"awac016","DOI":"10.1093\/brain\/awac016","article-title":"How patients with multiple sclerosis acquire disability","volume":"145","author":"Lublin","year":"2022","journal-title":"Brain"},{"key":"10.1016\/j.jns.2024.123356_bb0010","doi-asserted-by":"crossref","first-page":"43","DOI":"10.1016\/S0074-7742(07)79003-7","article-title":"The role of CD4 T cells in the pathogenesis of multiple sclerosis","volume":"79","author":"Chitnis","year":"2007","journal-title":"Int. Rev. Neurobiol."},{"key":"10.1016\/j.jns.2024.123356_bb0015","doi-asserted-by":"crossref","first-page":"696","DOI":"10.1038\/s41590-018-0135-x","article-title":"Reassessing B cell contributions in multiple sclerosis","volume":"19","author":"Li","year":"2018","journal-title":"Nat. Immunol."},{"key":"10.1016\/j.jns.2024.123356_bb0020","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1016\/S1474-4422(08)70192-3","article-title":"B cells and multiple sclerosis","volume":"7","author":"Franciotta","year":"2008","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123356_bb0025","doi-asserted-by":"crossref","DOI":"10.1172\/jci.insight.92724","article-title":"Clonal relationships of CSF B cells in treatment-naive multiple sclerosis patients","volume":"2","author":"Eggers","year":"2017","journal-title":"JCI Insight"},{"key":"10.1016\/j.jns.2024.123356_bb0030","doi-asserted-by":"crossref","first-page":"2755","DOI":"10.1093\/brain\/awr182","article-title":"Meningeal inflammation is widespread and linked to cortical pathology in multiple sclerosis","volume":"134","author":"Howell","year":"2011","journal-title":"Brain"},{"key":"10.1016\/j.jns.2024.123356_bb0035","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1056\/NEJMoa1601277","article-title":"Ocrelizumab versus Interferon Beta-1a in Relapsing Multiple Sclerosis","volume":"376","author":"Hauser","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123356_bb0040","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1056\/NEJMoa1606468","article-title":"Ocrelizumab versus placebo in primary progressive multiple sclerosis","volume":"376","author":"Montalban","year":"2017","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123356_bb0045","doi-asserted-by":"crossref","first-page":"1452","DOI":"10.1177\/13524585231195346","article-title":"Efficacy and safety of four-year ofatumumab treatment in relapsing multiple sclerosis: the ALITHIOS open-label extension","volume":"29","author":"Hauser","year":"2023","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2024.123356_bb0050","doi-asserted-by":"crossref","first-page":"1229","DOI":"10.1177\/13524585211055934","article-title":"Effect of ofatumumab versus placebo in relapsing multiple sclerosis patients from Japan and Russia: phase 2 APOLITOS study","volume":"28","author":"Kira","year":"2021","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2024.123356_bb0055","doi-asserted-by":"crossref","first-page":"546","DOI":"10.1056\/NEJMoa1917246","article-title":"Ofatumumab versus Teriflunomide in Multiple Sclerosis","volume":"383","author":"Hauser","year":"2020","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jns.2024.123356_bb0060","doi-asserted-by":"crossref","first-page":"13","DOI":"10.1002\/ana.25927","article-title":"Role of B Cells in Multiple Sclerosis and Related Disorders","volume":"89","author":"Comi","year":"2021","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2024.123356_bb0065","doi-asserted-by":"crossref","first-page":"120","DOI":"10.1093\/brain\/awy301","article-title":"Proinflammatory CD20+ T cells in the pathogenesis of multiple sclerosis","volume":"142","author":"von Essen","year":"2019","journal-title":"Brain"},{"key":"10.1016\/j.jns.2024.123356_bb0070","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000200004","article-title":"Ofatumumab modulates inflammatory T cell responses and migratory potential in patients with multiple sclerosis","volume":"9","author":"von Essen","year":"2022","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123356_bb0075","doi-asserted-by":"crossref","first-page":"310ra166","DOI":"10.1126\/scitranslmed.aab4176","article-title":"Bar-Or, on behalf of the C.B. Cells in team, Proinflammatory GM-CSF\u2013producing B cells in multiple sclerosis and B cell depletion therapy","volume":"7","author":"Li","year":"2015","journal-title":"Sci. Transl. Med."},{"key":"10.1016\/j.jns.2024.123356_bb0080","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1038\/s41582-021-00498-5","article-title":"B cells in multiple sclerosis \u2014 from targeted depletion to immune reconstitution therapies","volume":"17","author":"Cencioni","year":"2021","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2024.123356_bb0085","doi-asserted-by":"crossref","first-page":"1197","DOI":"10.1001\/jamaneurol.2021.2738","article-title":"Treatment escalation vs immediate initiation of highly effective treatment for patients with relapsing-remitting multiple sclerosis","volume":"78","author":"Spelman","year":"2021","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2024.123356_bb0090","doi-asserted-by":"crossref","first-page":"162","DOI":"10.1016\/S1474-4422(17)30470-2","article-title":"Diagnosis of multiple sclerosis: 2017 Revisions of the McDonald criteria","volume":"17","author":"Thompson","year":"2018","journal-title":"Lancet Neurol."},{"key":"10.1016\/j.jns.2024.123356_bb0095","doi-asserted-by":"crossref","first-page":"955","DOI":"10.1007\/s00234-020-02401-3","article-title":"A validation study of manual atrophy measures in patients with multiple sclerosis","volume":"62","author":"Cappelle","year":"2020","journal-title":"Neuroradiology"},{"key":"10.1016\/j.jns.2024.123356_bb0100","doi-asserted-by":"crossref","first-page":"171","DOI":"10.1038\/s41582-020-0314-x","article-title":"MAGNIMS consensus recommendations on the use of brain and spinal cord atrophy measures in clinical practice","volume":"16","author":"Sastre-Garriga","year":"2020","journal-title":"Nat. Rev. Neurol."},{"key":"10.1016\/j.jns.2024.123356_bb0105","doi-asserted-by":"crossref","DOI":"10.1212\/NXI.0000000000000456","article-title":"Normal brain imaging accompanies neuroimmunologically justified, autoimmune encephalomyelitis","volume":"5","author":"Takewaki","year":"2018","journal-title":"Neurol. - Neuroimmunol. Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123356_bb0110","article-title":"Prognostic accuracy of NEDA-3 in long-term outcomes of multiple sclerosis, Neurol.: Neuroimmunol","volume":"8","author":"Prosperini","year":"2021","journal-title":"Neuroinflammation"},{"key":"10.1016\/j.jns.2024.123356_bb0115","doi-asserted-by":"crossref","first-page":"1746","DOI":"10.1177\/1352458518809903","article-title":"Residual disability after severe relapse in people with multiple sclerosis treated with disease-modifying therapy","volume":"25","author":"Achiron","year":"2018","journal-title":"Mult. Scler. J."},{"key":"10.1016\/j.jns.2024.123356_bb0120","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1002\/ana.25463","article-title":"Silent progression in disease activity\u2013free relapsing multiple sclerosis","volume":"85","author":"U. of C. Team San Francisco MS-EPIC","year":"2019","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2024.123356_bb0125","doi-asserted-by":"crossref","first-page":"11","DOI":"10.2174\/1874205X01307010011","article-title":"Width of 3. Ventricle: reference values and clinical relevance in a cohort of patients with relapsing remitting multiple sclerosis","volume":"7","author":"M\u00fcller","year":"2013","journal-title":"Open Neurol. J."},{"key":"10.1016\/j.jns.2024.123356_bb0130","article-title":"Usefulness of two-dimensional measurements for the evaluation of brain volume and disability in multiple sclerosis","volume":"8","author":"Ajitomi","year":"2022","journal-title":"Mult. Scler. J. Exp., Transl. Clin."},{"key":"10.1016\/j.jns.2024.123356_bb0135","doi-asserted-by":"crossref","first-page":"1301","DOI":"10.1001\/archneur.63.9.1301","article-title":"Neocortical atrophy, third ventricular width, and cognitive dysfunction in multiple sclerosis","volume":"63","author":"Benedict","year":"2006","journal-title":"Arch. Neurol."},{"key":"10.1016\/j.jns.2024.123356_bb0140","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2019.101507","article-title":"Olfactory identification associates with cognitive function and the third ventricle width in patients with relapsing-remitting multiple sclerosis","volume":"38","author":"Okada","year":"2020","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123356_bb0145","doi-asserted-by":"crossref","first-page":"3181","DOI":"10.2169\/internalmedicine.8541-21","article-title":"Olfactory dysfunction reflects disease progression in Japanese patients with multiple sclerosis","volume":"61","author":"Okada","year":"2022","journal-title":"Intern. Med."},{"key":"10.1016\/j.jns.2024.123356_bb0150","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.103264","article-title":"Acting centrally or peripherally: A renewed interest in the central nervous system penetration of disease-modifying drugs in multiple sclerosis","volume":"56","author":"Correale","year":"2021","journal-title":"Mult. Scler. Relat. Disord."},{"key":"10.1016\/j.jns.2024.123356_bb0155","doi-asserted-by":"crossref","DOI":"10.1212\/WNL.0000000000207936","article-title":"Progression independent of relapse activity in multiple sclerosis","volume":"102","author":"Tur","year":"2024","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123356_bb0160","doi-asserted-by":"crossref","DOI":"10.1016\/j.ebiom.2023.104701","article-title":"B cell depletion therapy does not resolve chronic active multiple sclerosis lesions","volume":"94","author":"Maggi","year":"2023","journal-title":"EBioMedicine"},{"key":"10.1016\/j.jns.2024.123356_bb0165","doi-asserted-by":"crossref","first-page":"268","DOI":"10.1002\/ana.26281","article-title":"Spinal Cord Atrophy Predicts Progressive Disease in Relapsing Multiple Sclerosis","volume":"91","author":"Bischof","year":"2022","journal-title":"Ann. Neurol."},{"key":"10.1016\/j.jns.2024.123356_bb0170","doi-asserted-by":"crossref","first-page":"1398","DOI":"10.1001\/jamaneurol.2020.2453","article-title":"Association of Sustained Immunotherapy With Disability Outcomes in Patients With Active Secondary Progressive Multiple Sclerosis","volume":"77","author":"Lizak","year":"2020","journal-title":"JAMA Neurol."},{"key":"10.1016\/j.jns.2024.123356_bb0175","doi-asserted-by":"crossref","first-page":"1050","DOI":"10.1212\/WNL.0000000000004330","article-title":"Anti-inflammatory disease-modifying treatment and short-term disability progression in SPMS","volume":"89","author":"Lorscheider","year":"2017","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123356_bb0180","doi-asserted-by":"crossref","first-page":"e869","DOI":"10.1212\/WNL.0000000000012354","article-title":"Effects of high- and low-efficacy therapy in secondary progressive multiple sclerosis","volume":"97","author":"Roos","year":"2021","journal-title":"Neurology"},{"key":"10.1016\/j.jns.2024.123356_bb0190","doi-asserted-by":"crossref","DOI":"10.1016\/j.msard.2021.102988","article-title":"Anti-CD20 antibody therapy and risk of infection in patients with demyelinating diseases","volume":"52","author":"Oksbjerg","year":"2021","journal-title":"Mult. Scler. Relat. Disord."}],"container-title":["Journal of the Neurological Sciences"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24004921?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0022510X24004921?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,1,9]],"date-time":"2025-01-09T20:58:54Z","timestamp":1736456334000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0022510X24004921"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,1]]},"references-count":37,"alternative-id":["S0022510X24004921"],"URL":"https:\/\/doi.org\/10.1016\/j.jns.2024.123356","relation":{},"ISSN":["0022-510X"],"issn-type":[{"value":"0022-510X","type":"print"}],"subject":[],"published":{"date-parts":[[2025,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Ofatumumab for multiple sclerosis with disability accumulation","name":"articletitle","label":"Article Title"},{"value":"Journal of the Neurological Sciences","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jns.2024.123356","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2024 Elsevier B.V. All rights are reserved, including those for text and data mining, AI training, and similar technologies.","name":"copyright","label":"Copyright"}],"article-number":"123356"}}